• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >MUC1 immunotherapy is here to stay.
【24h】

MUC1 immunotherapy is here to stay.

机译：MUC1免疫疗法将继续存在。

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Success of HBV vaccines in reducing the incidence of liver cancer, and HPV vaccines in reducing preneoplastic cervical lesions, demonstrate the potential of cancer reduction by harnessing the immune system. For most human cancers, infectious etiology is not known but other tumor antigens, candidates for vaccines, have been identified. AREAS COVERED: The authors discuss knowledge accumulated the last two decades on the tumor antigen MUC1 that has put it at the top of the list as an immunotherapy reagent. They examine evidence that anti-MUC1 immunity affects tumor development and prognosis. Finally, they review two decades of immunotherapy trials targeting MUC1, focusing primarily on vaccines but also adoptive antibody and T-cell therapies. EXPERT OPINION: Most approaches targeting MUC1 have been immunotherapies administered to date to more than 1200 patients in clinical trials. Even though these trials focused on advanced cancer, encouraging results were reported particularly for less immunosuppressed patients. Furthermore, spontaneous anti-MUC1 immune responses are associated with better prognosis or with a reduced lifetime risk of developing MUC1+ cancers. MUC1 is abnormally expressed in over 80% of all cancers. Successfully targeting this molecule could benefit over a million patients diagnosed yearly with MUC1+ tumors just in the USA.
机译：简介：HBV疫苗在减少肝癌发病率方面的成功以及HPV疫苗在减少肿瘤前宫颈病变方面的成功，证明了通过利用免疫系统来减少癌症的潜力。对于大多数人类癌症，感染的病因尚不清楚，但已确定了其他肿瘤抗原（疫苗的候选物）。覆盖的领域：作者讨论了近二十年来有关肿瘤抗原MUC1的知识，该知识已将其作为免疫治疗试剂列首位。他们检查了抗MUC1免疫力影响肿瘤发展和预后的证据。最后，他们回顾了针对MUC1的二十年免疫疗法试验，主要关注疫苗，还关注过继抗体和T细胞疗法。专家意见：迄今为止，大多数针对MUC1的方法都是在临床试验中对1200多例患者进行了免疫治疗。即使这些试验的重点是晚期癌症，也报告了令人鼓舞的结果，尤其是对于免疫抑制程度较低的患者。此外，自发的抗MUC1免疫应答与更好的预后或降低的发生MUC1 +癌症的终生风险相关。 MUC1在所有癌症中的80％以上异常表达。仅在美国，成功靶向该分子可以使每年被诊断为MUC1 +肿瘤的百万患者受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号